

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claims 1-24 (canceled)

Claim 25 (new): A method of treating a patient with a cancer that has a BCRP-mediated resistance to an anticancer agent, which comprises preventing or reversing the BCRP-mediated resistance by administering to the patient an effective BCRP-inhibiting amount of imatinib or a pharmaceutically acceptable salt thereof.

Claim 26 (new) A method of claim 25 wherein the cancer that has a BCRP-mediated resistance to an anticancer agent is an osteosarcoma.

Claim 27 (new) A method of claim 25 wherein the anticancer agent is a camptothecin-derived topoisomerase I inhibitor.

Claim 28 (new) A method of claim 25 wherein the cancer is selected from the group consisting of colon cancer, breast cancer, liver cancer, ovarian cancer, fibrosarcoma, myeloma, acute myeloid leukemia, gastric cancer and non-small cell lung cancer.